

### This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Imaging</b>			
Monitoring response to preventive therapy in patients with Huntington's disease (HD) using <sup>18</sup> F-labeled fluorodeoxyglucose PET (FDG-PET) imaging	PET imaging of the brain could help monitor treatment responses in patients with presymptomatic and early symptomatic HD. In two independent cohorts of patients with HD, longitudinal <sup>18</sup> F-labeled FDG-PET imaging of multiple brain regions identified a pattern of region-specific increases and decreases in metabolic activity that were not seen in healthy individuals. The pattern intensified over time and correlated with years to onset, an empirical estimate of the time remaining until clinical symptoms of HD appear. Planned work includes validating the method in a two-year observational study of about 1,500 patients with presymptomatic HD.	Patent application filed by The Feinstein Institute for Medical Research; unlicensed	Tang, C.C. <i>et al. J. Clin. Invest.</i> ; published online Aug. 29, 2013; doi:10.1172/JCI69411 <b>Contact:</b> David Eidelberg, The Feinstein Institute for Medical Research, Manhasset, N.Y. e-mail: <a href="mailto:david1@nshs.edu">david1@nshs.edu</a>
	<b>SciBX 6(37); doi:10.1038/scibx.2013.1045</b> Published online Sept. 26, 2013		